 | |
- close
- close
|
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
WIKI ANALYSIS
Allos Therapeutics Inc. (Allos) is a biopharmaceutical company focused on developing and commercializing small molecule drugs for the treatment of cancer. The company strives to develop proprietary products that have the potential to improve the standard of care in cancer therapy. Allos' goal is to build a profitable company by generating income from products it develops and commercializes, either alone or with one or more potential strategic partners. The company's focus is on product opportunities that leverage its internal clinical development and regulatory expertise and address important markets with unmet medical need. Allos may also seek to grow its existing portfolio of product candidates through product acquisition and in-licensing efforts.
Allos has two product candidates that are currently under clinical development, PDX (pralatrexate) and RH1.
Candidate
Target Indications
Status
PDX:
Chemotherapy
Peripheral T-cell lymphoma
Phase II ongoing
Non-Hodgkin's lymphoma and Hodgkin's disease
Phase I/II ongoing
cutaneous T-cell lymphoma
Phase I/II ongoing
Stage IIIB/IV non small cell lung cancer
Phase I ongoing
RH1:
Chemotherapy
Solid Tumors
Phase I ongoing
Allos Therapeutics was incorporated in 1992 and is headquartered in Westminster, CO.
References
| ||||||
|
|
